Related Experiment Video

Updated: Aug 8, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

160

Prognostic significance of carbohydrate antigen 125 in stage D heart failure

Ji Zhang1, Wenhua Li2, Jianqiang Xiao2

  • 1Department of Cardiology, Wujin Hospital Affiliated With Jiangsu University, The Wujin Clinical College of Xuzhou Medical University, No. 2, Yongning Road, Changzhou, Jiangsu Province, China. js_zhangji@126.com.

BMC Cardiovascular Disorders
|February 25, 2023
PubMed

Insights

Elevated carbohydrate antigen 125 (CA125) levels predict mortality and heart failure (HF) readmission in stage D HF patients. This biomarker aids in risk stratification for improved patient management.

Area of Science:

  • Cardiology
  • Biomarkers
  • Prognostics

Background:

  • The prognostic value of carbohydrate antigen 125 (CA125) in stage D heart failure (HF) patients remains unexamined.
  • This study investigates CA125's predictive utility for mortality and HF readmission in this specific patient cohort, irrespective of left ventricular ejection fraction (LVEF).

Purpose of the Study:

  • To assess the prognostic significance of CA125 in predicting death and HF readmission among patients with stage D heart failure.
  • To evaluate CA125 as a potential tool for risk stratification in advanced heart failure.

Main Methods:

  • 176 stage D HF patients were divided into two groups based on CA125 levels relative to the median (65.7 U/ml).
  • Patient outcomes, including all-cause death, cardiovascular mortality, HF readmission, and major adverse cardiovascular events (MACE), were tracked over an 18-month follow-up period.
  • Kaplan-Meier and Cox regression analyses were employed to determine the prognostic value of CA125.

Main Results:

  • Patients with CA125 ≥ 65.7 U/ml exhibited significantly higher 1-year mortality (59.3% vs. 31.0%) and death/HF rehospitalization rates (94.2% vs. 80.6%).
  • CA125 was identified as a significant prognostic factor for all-cause death, cardiovascular mortality, death/HF readmission, and MACE in both univariate and multivariate analyses.
  • A substantial proportion of patients (89.2%) experienced adverse events, including death or HF readmission, within the follow-up period.

Conclusions:

  • Elevated CA125 levels are highly predictive of adverse outcomes in stage D HF patients.
  • CA125 can serve as a valuable biomarker for enhanced risk stratification in advanced heart failure, guiding clinical decision-making.
Abstract

Keywords:
Carbohydrate antigen 125PrognosisStage D heart failure

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
134
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
21
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K